[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 28, 1994

Tacrine for Alzheimer's Disease-Reply

Author Affiliations

Senior Editor, JAMA

JAMA. 1994;272(24):1897-1898. doi:10.1001/jama.1994.03520240024024
Abstract

In Reply.  —In response to Dr Wolferman and Dr Temianka, JAMA recognizes that pharmaceutical manufacturers conducting studies on drugs they manufacture have a vested interest in demonstrating efficacy of the drug. Conflicts of interest may be obvious, as in this case, or more subtle.1 Therefore, JAMA requires all authors to sign the financial disclosure statement2 and includes all pertinent information in a footnote as part of the article. However, simply because an individual or company has a conflict does not mean they cannot conduct legitimate research. One purpose of editing and peer review is to evaluate reports of studies for possible biases and flaws and select those with the best science. This study met that test. Specific criteria to assess the quality of drug studies in the literature were recently published by Cho and Bero.3Investigators increasingly must depend on nongovernmental funds to conduct research. We choose

First Page Preview View Large
First page PDF preview
First page PDF preview
×